Projects per year
Abstract / Description of output
METHODS: We studied the effect of a second-generation flavonoid analogue Oncamex in a panel of seven breast cancer cell lines, applying western blotting, gene expression analysis, fluorescence microscopy and immunohistochemistry of xenograft tissue to investigate its mechanism of action.
RESULTS: Proliferation assays showed that Oncamex treatment for 8 h reduced cell viability and induced cytotoxicity and apoptosis, concomitant with increased caspase activation. Microarray analysis showed that Oncamex was associated with changes in the expression of genes controlling cell cycle and apoptosis. Fluorescence microscopy showed the compound's mitochondrial targeting and reactive oxygen species-modulating properties, inducing superoxide production at concentrations associated with antiproliferative effects. A preliminary in vivo study in mice implanted with the MDA-MB-231 breast cancer xenograft showed that Oncamex inhibited tumour growth, reducing tissue viability and Ki-67 proliferation, with no signs of untoward effects on the animals.
CONCLUSIONS: Oncamex is a novel flavonoid capable of specific mitochondrial delivery and redox modulation. It has shown antitumour activity in preclinical models of breast cancer, supporting the potential of this prototypic candidate for its continued development as an anticancer agent.British Journal of Cancer advance online publication, 31 March 2016; doi:10.1038/bjc.2016.6 www.bjcancer.com.
FingerprintDive into the research topics of 'Antitumour Activity of the Novel Flavonoid Oncamex in Preclinical Breast Cancer Models'. Together they form a unique fingerprint.
- 2 Finished
Harrison, D. & Langdon, S.
1/09/12 → 31/08/16
1/02/09 → 31/07/14
- Deanery of Molecular, Genetic and Population Health Sciences - Visitor: Official Visitor
- Edinburgh Pathology
- Edinburgh Cancer Research Centre
Person: Academic: Research Active , Affiliated Independent Researcher